CATALOGO DEI PRODOTTI DELLA RICERCA

FRACASSO, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.634
EU - Europa 5.726
AS - Asia 4.519
SA - Sud America 618
Continente sconosciuto - Info sul continente non disponibili 126
AF - Africa 111
OC - Oceania 9
Totale 18.743
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.341
RU - Federazione Russa 2.033
SG - Singapore 1.769
CN - Cina 1.307
GB - Regno Unito 1.290
IT - Italia 593
BR - Brasile 496
VN - Vietnam 432
HK - Hong Kong 378
FR - Francia 328
SE - Svezia 322
IE - Irlanda 297
DE - Germania 280
FI - Finlandia 240
CA - Canada 166
KR - Corea 151
UA - Ucraina 84
IN - India 80
TR - Turchia 60
BD - Bangladesh 59
JP - Giappone 56
MX - Messico 48
NL - Olanda 46
AR - Argentina 45
PL - Polonia 40
ID - Indonesia 37
ES - Italia 32
BE - Belgio 30
IQ - Iraq 30
NG - Nigeria 27
ZA - Sudafrica 26
IR - Iran 23
PK - Pakistan 20
EC - Ecuador 19
SA - Arabia Saudita 15
CO - Colombia 14
CR - Costa Rica 14
PH - Filippine 14
AT - Austria 12
JM - Giamaica 12
LT - Lituania 12
VE - Venezuela 12
CH - Svizzera 11
GT - Guatemala 11
MA - Marocco 11
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
GR - Grecia 9
MY - Malesia 9
UY - Uruguay 9
CL - Cile 8
EG - Egitto 8
TT - Trinidad e Tobago 8
AU - Australia 7
BY - Bielorussia 7
HR - Croazia 7
JO - Giordania 7
PE - Perù 7
PT - Portogallo 7
SV - El Salvador 7
TN - Tunisia 7
AZ - Azerbaigian 6
PR - Porto Rico 6
PY - Paraguay 6
AL - Albania 5
DK - Danimarca 5
DZ - Algeria 5
HN - Honduras 5
KE - Kenya 5
RO - Romania 5
TW - Taiwan 5
CW - ???statistics.table.value.countryCode.CW??? 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
IL - Israele 4
KW - Kuwait 4
KZ - Kazakistan 4
LV - Lettonia 4
NI - Nicaragua 4
NP - Nepal 4
PA - Panama 4
BJ - Benin 3
CZ - Repubblica Ceca 3
EE - Estonia 3
EU - Europa 3
LU - Lussemburgo 3
OM - Oman 3
SN - Senegal 3
TG - Togo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
BS - Bahamas 2
CI - Costa d'Avorio 2
CM - Camerun 2
CY - Cipro 2
GP - Guadalupe 2
KG - Kirghizistan 2
Totale 18.590
Salva come PNG Salva come JPEG
Città #
Southend 1.073
Ashburn 1.049
Singapore 931
Moscow 701
Dallas 662
Chandler 644
San Jose 625
Jacksonville 565
Woodbridge 408
Hong Kong 363
Dublin 294
Ann Arbor 281
Verona 269
Beijing 248
Council Bluffs 231
Houston 209
The Dalles 177
Ho Chi Minh City 135
New York 118
Los Angeles 110
Lawrence 107
Princeton 106
Wilmington 102
Jinan 92
Hanoi 84
Nanjing 80
Santa Clara 71
Buffalo 66
Shenyang 65
São Paulo 64
Tianjin 64
Helsinki 63
Tokyo 52
Hebei 49
Changsha 43
Columbus 42
Munich 41
Montreal 39
Sindelfingen 39
Seoul 37
Zhengzhou 37
Dong Ket 35
Milan 35
Orem 35
Denver 34
London 34
Chennai 33
Toronto 33
Seattle 32
Warsaw 32
Boardman 31
Atlanta 29
Brussels 29
Redondo Beach 29
Guangzhou 28
Jakarta 27
Chicago 26
San Francisco 26
Haikou 25
Ningbo 25
Hangzhou 24
Jiaxing 24
Abuja 23
Brooklyn 23
Redwood City 23
Rome 23
Boston 22
Frankfurt am Main 22
Taizhou 22
Bologna 21
Johannesburg 21
Taiyuan 21
Stockholm 20
Turku 20
Da Nang 19
Nanchang 19
Amsterdam 18
Lancaster 18
Norwalk 18
Paris 17
Fuzhou 16
Rio de Janeiro 15
Vancouver 15
Phoenix 14
Redmond 14
Falkenstein 13
Manchester 13
Montréal 13
Padova 13
Shanghai 13
Mexico City 12
Nuremberg 12
Poplar 12
Washington 12
Brasília 11
Guatemala City 11
Newark 11
North Bergen 11
Philadelphia 11
Providence 11
Totale 11.685
Salva come PNG Salva come JPEG
Nome #
Anti PSMA immunotoxins activity against prostate cancer cell lines. 305
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 282
Anti-PSMA-Immunotoxins: a new therapeutical strategy for selective targeting of toxins to prostate cancer cells. 281
Immunotoxins and other conjugates: preparation and general characteristics. 279
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 276
Reductive activation of ricin and ricin-A chain immunotoxins by Protein Disulfide Isomerase and Thioredoxin Reductase system. 258
Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells 258
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 246
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 244
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 242
A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia 238
Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells 235
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 232
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 232
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 226
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 225
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 224
Characterization of In-111-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors 224
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 219
Protein Disulfide Isomerase and Thioredoxin Reductase: a ricin disulfide reducing system in the endoplasmic reticulum. 211
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 211
Biodistribution of In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice bearing human prostate cancer xenografts 210
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 210
Targeted Killing of Prostate Cancer Cells using Antibody-Drug conjugated Carbon Nanohorns 210
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin 209
Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors 208
The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells. 206
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 205
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 204
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 202
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 201
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 199
Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen 199
Top-down synthesis of multifunctional iron oxide nanoparticles for macrophage labelling and manipulation 195
Acute sarcomeric M-Line Disease associated with ATP synthase subunit α autoantibodies in ankylosing spondylitis 194
Prostate Specific Membrane Antigen (PSMA) associates with Filamin A, beta1 integrin, pp130CAS and pSrc thus regulating the activation of beta1 integrin and the survival of prostate cancer cells. 193
Cloning and characterisation of canine prostate-specific membrane antigen 191
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors 191
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. 190
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 188
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 187
N-terminal deletion affetcs catalytic activity of saporin toxin. 186
Plasmonic Nanostructures for SERRS Multiplexed Identification of Tumor-Associated Antigens 186
Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems 186
Prostate-specific membrane antigen associates already in the endoplasmic reticulum with lipid microdomains 186
An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. 182
Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. 179
Magneto-Plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging 178
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker 177
SERS IMAGING OF CANCER CELLS WITH ANTIBODY FUNCTIONALIZED GOLD NANOPARTICLES 175
Targeted Silica Nanoparticles for PhotoDynamic Therapy (PDT) 174
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer 174
Pegylated silica nanoparticles: cytotoxicity and macrophage uptake 172
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 171
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures 171
Identification of Ricin A chain HLA II-restricted epitopes by human T-cell clones. 166
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) 166
Prostate-specific membrane antigen (PSMA) associates early in the endoplasmic reticulum with lipid microdomains 165
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extendash}Part I 162
Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies 159
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection 157
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents 154
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin 152
Gangliosides act as onconeural antigens in paraneoplastic neuropathies. 150
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones 149
SERS labels for quantitative assays: application to the quantification of gold nanoparticles uptaken by macrophage cells 148
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. 147
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 146
Prostate-specific membrane antigen routing to the cell surface implicates an early association step in the endoplasmic reticulum with lipid microdomains. 145
Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy 139
Laser generated gold nanocorals with broadband plasmon absorption for photothermal applications 137
Safe Core-Satellite Magneto-Plasmonic Nanostructures for Efficient Targeting and Photothermal Treatment of Tumor Cells 137
SERRS Multiplexing with Multivalent Nanostructures for the Identification and Enumeration of Epithelial and Mesenchymal Cells 136
Effect of therapeutic macromolecules in spheroids 134
Improved method for carbohydrate-deficient transferrin determination in human serum by capillary zone electrophoresis 134
Simple and Rapid Non-Enzymatic Procedure Allows the Isolation of Structurally Preserved Connective Tissue Micro-Fragments Enriched with SVF 134
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model 134
Pharmacokinetics of intrathecal transferrin-ricin A chain immunotoxins 133
Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates. 133
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model 133
The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity 133
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe 132
PSMA as a new target for anti-vascular therapy. Development of an in vitro model of PSMA positive endothelial cells. 132
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells 132
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 130
G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children 126
Ribosome-inactivating protein-containing conjugates for therapeutic use 126
Efficient AuFeOx Nanoclusters of Laser-Ablated Nanoparticles in Water for Cells Guiding and Surface-Enhanced Resonance Raman Scattering Imaging 125
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extemdash}Part {II}. Toxicity, Pharmacokinetics and Biodistribution 122
Immunology of RIPs and their Immunotoxins, in Ribosome-inactivating Proteins: Ricin and Related Proteins 120
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 120
Dual modality imaging of PSMA-expressing prostate cancer with a new radiolabeled anti-PSMA monoclonal antibody conjugated with IRDye800CW 115
Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness 115
New Tc-99m-radioimmunoconjugates for pancreatic carcinoma detection 113
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging 113
Targeting prostate cancer cells with D2B-gold Nanoparticles 112
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors 112
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma 110
Different Glycoforms of Prostate-Specific Membrane Antigen are intracellularly transported through their Association with Distinct Detergent-Resistant Membranes 108
D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer 108
Totale 17.691
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.926
article - articoli 45.543
book - libri 0
conference - conferenze 14.343
curatela - curatele 0
other - altro 0
patent - brevetti 1.080
selected - selezionate 0
volume - volumi 960
Totale 123.852
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022541 0 0 0 81 37 18 16 51 20 33 74 211
2022/20231.892 147 181 171 322 136 457 74 130 200 13 46 15
2023/2024898 43 85 91 94 109 122 35 55 12 79 123 50
2024/20252.436 113 153 61 367 169 82 123 112 403 186 223 444
2025/20267.234 506 447 618 1.103 1.808 498 723 345 508 408 102 168
2026/20271.431 104 184 340 803 0 0 0 0 0 0 0 0
Totale 18.743